Definium Therapeutics (DFTX) Research & Development (2019 - 2026)

Definium Therapeutics (DFTX) has 7 years of Research & Development data on file, last reported at $41.5 million in Q1 2026.

• Research & Development for Q1 2026 came in at $41.5 million, up 77.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $135.8 million (up 76.51% YoY), and the FY2025 annual result was $117.7 million, up 80.25% from the prior year.
• Research & Development improved to $41.5 million in Q1 2026 per DFTX's latest filing, from $33.6 million in the prior quarter.
• Over five years, Research & Development peaked at $41.5 million in Q1 2026 and troughed at $7.8 million in Q3 2022.
• A 5-year average of $18.4 million and a median of $14.6 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development retreated 18.86% in 2022, then surged 103.54% in 2025.
• A 5-year view of Research & Development shows it stood at $8.8 million in 2022, then jumped by 30.76% to $11.5 million in 2023, then jumped by 88.48% to $21.8 million in 2024, then soared by 54.2% to $33.6 million in 2025, then gained by 23.63% to $41.5 million in 2026.
• Business Quant data shows DFTX's Research & Development at $41.5 million in Q1 2026, $33.6 million in Q4 2025, and $31.0 million in Q3 2025.